Comparison of Ba-Duan-Jin and Pregabalin in Patients With Fibromyalgia

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Fibromyalgia is a chronic debilitating musculoskeletal pain syndrome. Pregabalin is the only medication that has been approved to treat fibromyalgia in China. Currently, there has been a growing interest in the development of non-pharmacological therapies. Ba-Duan-Jin is an ancient Chinese exercise for health promotion yet easy to learn. Findings from our previous study showed an effectiveness and good safety of Ba-Duan-Jin in patients with fibromyalgia. This study is to evaluate the effectiveness comparison of Ba-Duan-Jin and pregabalin in managing fibromyalgia symptoms experienced by Chinese patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for fibromyalgia;

• be between the ages of 18 to 70 years.

Exclusion Criteria:

• had practiced Ba-Duan-Jin, Tai Chi, yoga or other forms of Qigong exercise within 12 months of their recruitment to the study;

• be less than 40mm of pain VAS score;

• had renal failure, and severe depression or anxiety;

• had any poorly-controlled comorbid medical conditions, such as dementia, cancer, thyroid disease, inflammatory arthritis;

• pregnancy or planned pregnancy within the study period;

• patients residing more than 70 miles from the research site.